Summary
The MICs of amoxicillin, mezlocillin and BRL 25,000, a combination of two parts amoxicillin and one part clavulanic acid (2AM + 1CA), were measured for 331Enterobacteriaceae strains which produced beta-lactamases as demonstrated by nitrocefin. The MIC values for mezlocillin and the combination 2AM + 1CA were very similar for the total number of the strains investigated. When investigated separately according to the bacterial species, three different sensitivity groups were established for the above-mentioned preparations: 1) species with the same or similar sensitivity to mezlocillin and 2AM + 1CA (Escherichia coli andShigella spp., amoxicillin-resistant strains); 2) species which were more sensitive to mezlocillin than to the combination 2AM + 1CA (Citrobacter spp.,Enterobacter cloacae, Serratia spp. and indole-positiveProteus as well as strains ofE. coli andShigella spp. which produce a cephalosporinase and are sensitive to amoxicillin); 3) species which are more sensitive to 2AM + 1CA than to mezlocillin (amoxicillin-resistantSalmonella spp.,Proteus mirabilis andKlebsiella pneumoniae). This complementary activity of mezlocillin and 2AM + 1CA againstEnterobacteriaceae depended on the beta-lactamases produced.
Zusammenfassung
Die MHK für Amoxicillin, Mezlocillin und BRL 25000 sowie eine Kombination von zwei Teilen Amoxicillin plus einem Teil Clavulansäure (2AM + 1CA) wurde für 331Enterobacteriaceae-Stämme getestet; alle diese Stämme produzierten β-Laktamasen, die mit Nitrocefin nachgewiesen worden waren. Die MHK-Werte für Mezlocillin und die Kombination 2AM + 1CA waren bei den untersuchten Stämmen insgesamt sehr ähnlich. Bei der getrennten Auswertung nach Stämmen und Keimarten ergeben sich für die überprüften Wirkstoffe drei Empfindlichkeitsgruppen: 1) Keimarten mit der gleichen oder einer ähnlichen Empfindlichkeit für Mezlocillin und 2AM + 1CA (Escherichia coli, Shigella spp., Amoxicillin-resistente Stämme), 2) Keimarten, die für Mezlocillin empfindlicher waren als für die Kombination 2AM + 1CA (Citrobacter spp.,Enterobacter cloacae, Serratia spp., indolpositiveProteus spp. sowie solche Stämme vonE. coli undShigella spp., die eine Cephalosporinase produzieren und auf Amoxicillin ansprechen), 3) Keimarten, die für 2AM + 1CA empfindlicher sind als für Mezlocillin (Amoxicillin-resistenteSalmonella spp.,Proteus mirabilis undKlebsiella pneumoniae). Diese deutliche komplementäre Wirkung von Mezlocillin und 2AM + 1CA aufEnterobacteriaceae hängt von den Stammeigenschaften und der gebildeten β-Laktamase ab.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literature
Brown, A. G. New naturally occurring β-lactam antibiotics and related compounds. J. Antimicrob. Chemother. 7 (1981) 15–48.
Roy, C., Segura, C., Fuster, C., Tirado, M., Foz, A. Espectro antibacteriano de dos ureidopenicilinas: mezlocilina y azlocilina. Med. Clín. (Barc.) 78 (1982) 363–371.
Roy, C., Segura, C., Tirado, M., Fuster, C., Foz, A. Actividad del preparado BRL 25,000 (amoxicilina + ácido clavulánico) frente a cepas deEnterobacteriaceae formadoras de betalactamasa. Estudiosin vitro. Med. Clín. (Barc.) 78 (1982) 189–195.
Foz, A., Roy, C., Segura, C., Fuster, C., Tirado M. Estudios sobre la actividad antibacteriana de la cefotaxima (HR 756), nuevo antibiótico del grupo de las cefalosporinas. Med. Clín. (Barc.) 75 (1980) 373–379.
Pechere, J. C., Letarte, R., Guay, R. Inhibitory activity of clavulanic acid against 16 β-lactamases produced by gram-negative bacteria. In:Nelson, J. D., Grassi, C. (eds.): Current Chemotherapy and Infectious Disease. American Society for Microbiology, Washington, D. C. 1980, pp. 323–326.
Van Landuyt, H. W., Lambert, A. Comparative activity of BRL 25,000 with amoxicillin against resistant clinical isolates. In:Nelson, J. D., Grassi, C. (eds.): Current Chemotherapy and Infectious Disease. American Society for Microbiology, Washington, D. C. 1980, pp. 334–336.
Comber, K. R., Horton, R., Mizen, L., White, A. R., Sutherland, R. Activity of amoxicillin/clavulanic acid (2:1) [BRL 25,000, Augmentin]in vitro andin vivo. In:Nelson, J. D., Grassi, C. (eds.): Current Chemotherapy and Infectious Disease. American Society for Microbiology, Washington, D. C. 1980, pp. 343–344.
Hunter, P. A., Coleman, K., Fisher, J., Taylor, D. In vitro synergistic properties of clavulanic acid with ampicillin, amoxicillin and ticarcillin. J. Antimicrob. Chemother. 6 (1980) 455–470.
Philippon, A. M., Paul, G. C., Nevot, P. A. Synergy of clavulanic acid with penicillin against ampicillin and carbenicillin resistant gram-negative organisms, related to their type of beta-lactamase. In:Nelson, J. D., Grassi, C. (eds.): Current Chemotherapy and Infectious Disease. American Society for Microbiology, Washington, D. C. 1980, pp. 327–329.
Witchitz, J. L., Faurisson, F., Christol, D. Sensibilité des bacilles gram-négatifs aérobies aux nouvelles penicillines semi-synthétiques: ticarcilline, mezlocilline, azlocilline, piperacilline, selon les phénotypes de résistance aux β-lactamines usuelles. Méd. Maladies Infectieuses 10 (1980) 287–293.
Wise, R., Gillett, A. P., Andrews, J. M. Thein vitro activity of mezlocillin when combined with cefoxitin or clavulanic acid. J. Antimicrob. Chemother. 5 (1979) 301–306.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Roy, C., Foz, A., Tirado, M. et al. Complementary activity of mezlocillin and the combination of amoxicillin with clavulanic acid on Enterobacteriaceae. Infection 10 (Suppl 3), S262–S266 (1982). https://doi.org/10.1007/BF01640685
Issue Date:
DOI: https://doi.org/10.1007/BF01640685